Chugai Pharmaceutical's operating profit FY 2013-2022
The Japanese company Chugai Pharmaceutical Co., Ltd reported an operating profit of approximately 452.7 billion Japanese yen in fiscal year 2022, its highest profits of the past decade. The company is expecting a further growth of the operating profit from royalty income for the internally developed product "Hemlibra".